vs
ENANTA PHARMACEUTICALS INC（ENTA）与ROCKWELL MEDICAL, INC.（RMTI）财务数据对比。点击上方公司名可切换其他公司
ENANTA PHARMACEUTICALS INC的季度营收约是ROCKWELL MEDICAL, INC.的1.0倍（$18.6M vs $18.3M），ROCKWELL MEDICAL, INC.净利率更高（-3.0% vs -64.1%，领先61.1%），ENANTA PHARMACEUTICALS INC同比增速更快（9.8% vs -25.6%），ROCKWELL MEDICAL, INC.自由现金流更多（$2.2M vs $-11.8M），过去两年ENANTA PHARMACEUTICALS INC的营收复合增速更高（4.5% vs -10.1%）
Enanta制药是一家临床阶段生物技术企业，专注于研发针对乙型肝炎病毒、呼吸道合胞病毒、新冠病毒等传染性疾病的创新抗病毒疗法，与全球制药伙伴合作推进小分子候选药物管线，满足未被覆盖的临床需求。
罗克韦尔医疗成立于1996年，总部位于美国密歇根州威克瑟姆，是一家上市制药企业，核心业务聚焦于终末期肾病与慢性肾病相关治疗方案的研发与商业化推广。
ENTA vs RMTI — 直观对比
营收规模更大
ENTA
是对方的1.0倍
$18.3M
营收增速更快
ENTA
高出35.4%
-25.6%
净利率更高
RMTI
高出61.1%
-64.1%
自由现金流更多
RMTI
多$14.0M
$-11.8M
两年增速更快
ENTA
近两年复合增速
-10.1%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $18.6M | $18.3M |
| 净利润 | $-11.9M | $-554.0K |
| 毛利率 | — | 21.1% |
| 营业利润率 | -60.5% | -2.2% |
| 净利率 | -64.1% | -3.0% |
| 营收同比 | 9.8% | -25.6% |
| 净利润同比 | 46.4% | 26.7% |
| 每股收益（稀释后） | $-0.42 | $-0.01 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ENTARMTI
| Q4 25 | $18.6M | $18.3M | ||
| Q3 25 | $15.1M | $15.9M | ||
| Q2 25 | $18.3M | $16.1M | ||
| Q1 25 | $14.9M | $18.9M | ||
| Q4 24 | $17.0M | $24.7M | ||
| Q3 24 | $14.6M | $28.3M | ||
| Q2 24 | $18.0M | $25.8M | ||
| Q1 24 | $17.1M | $22.7M |
净利润ENTARMTI
| Q4 25 | $-11.9M | $-554.0K | ||
| Q3 25 | $-18.7M | $-1.8M | ||
| Q2 25 | $-18.3M | $-1.5M | ||
| Q1 25 | $-22.6M | $-1.5M | ||
| Q4 24 | $-22.3M | $-756.0K | ||
| Q3 24 | $-28.8M | $1.7M | ||
| Q2 24 | $-22.7M | $343.0K | ||
| Q1 24 | $-31.2M | $-1.7M |
毛利率ENTARMTI
| Q4 25 | — | 21.1% | ||
| Q3 25 | — | 14.3% | ||
| Q2 25 | — | 15.6% | ||
| Q1 25 | — | 16.1% | ||
| Q4 24 | — | 14.7% | ||
| Q3 24 | — | 22.0% | ||
| Q2 24 | — | 17.6% | ||
| Q1 24 | — | 13.5% |
营业利润率ENTARMTI
| Q4 25 | -60.5% | -2.2% | ||
| Q3 25 | -121.6% | -9.9% | ||
| Q2 25 | -103.2% | -8.4% | ||
| Q1 25 | -164.3% | -7.2% | ||
| Q4 24 | -138.8% | -2.1% | ||
| Q3 24 | -204.4% | 6.8% | ||
| Q2 24 | -134.6% | 2.0% | ||
| Q1 24 | -192.1% | -5.8% |
净利率ENTARMTI
| Q4 25 | -64.1% | -3.0% | ||
| Q3 25 | -123.6% | -11.0% | ||
| Q2 25 | -99.7% | -9.3% | ||
| Q1 25 | -151.7% | -8.0% | ||
| Q4 24 | -131.4% | -3.1% | ||
| Q3 24 | -197.3% | 5.9% | ||
| Q2 24 | -126.1% | 1.3% | ||
| Q1 24 | -182.7% | -7.6% |
每股收益（稀释后）ENTARMTI
| Q4 25 | $-0.42 | $-0.01 | ||
| Q3 25 | $-0.88 | $-0.05 | ||
| Q2 25 | $-0.85 | $-0.05 | ||
| Q1 25 | $-1.06 | $-0.04 | ||
| Q4 24 | $-1.05 | $-0.02 | ||
| Q3 24 | $-1.36 | $0.04 | ||
| Q2 24 | $-1.07 | $0.01 | ||
| Q1 24 | $-1.47 | $-0.06 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $37.4M | $10.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $126.6M | $37.0M |
| 总资产 | $329.5M | $57.1M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ENTARMTI
| Q4 25 | $37.4M | $10.7M | ||
| Q3 25 | $32.3M | $13.6M | ||
| Q2 25 | $44.8M | $12.5M | ||
| Q1 25 | $60.2M | $11.4M | ||
| Q4 24 | $84.3M | $15.7M | ||
| Q3 24 | $37.2M | $12.3M | ||
| Q2 24 | $35.8M | $11.9M | ||
| Q1 24 | $63.5M | $6.6M |
股东权益ENTARMTI
| Q4 25 | $126.6M | $37.0M | ||
| Q3 25 | $64.7M | $37.0M | ||
| Q2 25 | $79.3M | $30.4M | ||
| Q1 25 | $93.5M | $31.5M | ||
| Q4 24 | $111.8M | $32.6M | ||
| Q3 24 | $128.8M | $29.1M | ||
| Q2 24 | $148.9M | $23.5M | ||
| Q1 24 | $166.1M | $20.6M |
总资产ENTARMTI
| Q4 25 | $329.5M | $57.1M | ||
| Q3 25 | $280.7M | $57.5M | ||
| Q2 25 | $301.0M | $52.6M | ||
| Q1 25 | $323.0M | $54.0M | ||
| Q4 24 | $348.6M | $59.2M | ||
| Q3 24 | $376.7M | $57.1M | ||
| Q2 24 | $398.8M | $53.0M | ||
| Q1 24 | $413.6M | $50.7M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-11.7M | $2.3M |
| 自由现金流经营现金流 - 资本支出 | $-11.8M | $2.2M |
| 自由现金流率自由现金流/营收 | -63.6% | 12.0% |
| 资本支出强度资本支出/营收 | 0.8% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-18.5M | $-1.2M |
8季度趋势，按日历期对齐
经营现金流ENTARMTI
| Q4 25 | $-11.7M | $2.3M | ||
| Q3 25 | $-6.5M | $-1.3M | ||
| Q2 25 | $17.5M | $1.8M | ||
| Q1 25 | $-13.5M | $-3.5M | ||
| Q4 24 | $-16.8M | $865.0K | ||
| Q3 24 | $-10.4M | $4.3M | ||
| Q2 24 | $-14.8M | $1.4M | ||
| Q1 24 | $-28.6M | $-2.4M |
自由现金流ENTARMTI
| Q4 25 | $-11.8M | $2.2M | ||
| Q3 25 | $-7.9M | $-1.5M | ||
| Q2 25 | $17.4M | $1.7M | ||
| Q1 25 | $-16.0M | $-3.5M | ||
| Q4 24 | $-25.5M | $470.0K | ||
| Q3 24 | $-19.4M | $4.1M | ||
| Q2 24 | $-21.3M | $1.2M | ||
| Q1 24 | $-30.3M | $-2.5M |
自由现金流率ENTARMTI
| Q4 25 | -63.6% | 12.0% | ||
| Q3 25 | -52.5% | -9.6% | ||
| Q2 25 | 94.7% | 10.5% | ||
| Q1 25 | -107.4% | -18.8% | ||
| Q4 24 | -150.6% | 1.9% | ||
| Q3 24 | -132.5% | 14.4% | ||
| Q2 24 | -118.6% | 4.5% | ||
| Q1 24 | -177.5% | -11.1% |
资本支出强度ENTARMTI
| Q4 25 | 0.8% | 0.5% | ||
| Q3 25 | 9.6% | 1.4% | ||
| Q2 25 | 0.8% | 1.0% | ||
| Q1 25 | 17.0% | 0.3% | ||
| Q4 24 | 51.6% | 1.6% | ||
| Q3 24 | 61.3% | 0.7% | ||
| Q2 24 | 36.4% | 1.1% | ||
| Q1 24 | 9.8% | 0.6% |
现金转化率ENTARMTI
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 2.57× | ||
| Q2 24 | — | 4.20× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ENTA
暂无分部数据
RMTI
| US | $15.9M | 87% |
| Non Us | $2.4M | 13% |
